Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS105 combination therapy study in advanced solid tumors
CTR20233790Phase 2Active
- Sponsor
- Junshi Risen
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS105 in breast cancer, endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer, fallopian tube cancer (PFTC), sponsored by Junshi Risen. Started Jan 2024; status: active.
02
Drugs
JS105
03
Conditions
breast cancerendometrial cancer (EC)Cervical Cancer (CC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20233790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233790.